Integrin 3D structures: Difference between revisions
Jump to navigation
Jump to search
Michal Harel (talk | contribs) No edit summary |
Michal Harel (talk | contribs) No edit summary |
||
(2 intermediate revisions by the same user not shown) | |||
Line 53: | Line 53: | ||
**[[2vdm]], [[2vdn]], [[3t3m]], [[3t3p]] – hIG headpiece + antibody + antagonist + Mg<br /> | **[[2vdm]], [[2vdn]], [[3t3m]], [[3t3p]] – hIG headpiece + antibody + antagonist + Mg<br /> | ||
**[[2vdo]], [[2vdp]], [[2vdq]], [[2vdr]] – hIG headpiece + antibody + fibrinogen peptide + Mg<br /> | **[[2vdo]], [[2vdp]], [[2vdq]], [[2vdr]] – hIG headpiece + antibody + fibrinogen peptide + Mg<br /> | ||
**[[6v4p]] – hIG + antibody – Cryo-EM<br /> | **[[6v4p]], [[7la4]] – hIG + antibody – Cryo-EM<br /> | ||
**[[7l8p]], [[7tct]], [[7td8]], [[7tho]], [[7tmz]], [[7tpd]], [[7u60]], [[7u9f]], [[7u9v]], [[7ubr]], [[7ucy]], [[7udg]], [[7udh]], [[7ue0]], [[7ufh]], [[7uh8]], [[7uje]], [[7ujk]], [[7uk9]], [[7uko]], [[7ukp]], [[7ukt]] – hIG + antibody + drug<br /> | |||
*IG α-4 | *IG α-4 | ||
Line 95: | Line 96: | ||
**[[1lfa]] - hIG I domain + Mn <br /> | **[[1lfa]] - hIG I domain + Mn <br /> | ||
**[[1zon]], [[4ixd]] - hIG I domain <br /> | **[[1zon]], [[4ixd]], [[7kc3]] - hIG I domain 153-334 <br /> | ||
**[[1mqa]] - hIG I domain (mutant) <br /> | **[[1mqa]] - hIG I domain (mutant) <br /> | ||
**[[1zoo]], [[1zop]], [[3f74]] - hIG I domain + Mg <br /> | **[[1zoo]], [[1zop]], [[3f74]] - hIG I domain + Mg <br /> | ||
Line 111: | Line 112: | ||
**[[1rd4]], [[2ica]], [[3bqm]], [[3bqn]], [[3e2m]] - hIG I domain + inhibitor<br /> | **[[1rd4]], [[2ica]], [[3bqm]], [[3bqn]], [[3e2m]] - hIG I domain + inhibitor<br /> | ||
**[[2o7n]], [[3m6f]] - hIG I domain + antagonist<br /> | **[[2o7n]], [[3m6f]] - hIG I domain + antagonist<br /> | ||
**[[1xdd]], [[1xdg]], [[1xuo]] - hIG I domain + inhibitor + Mg<br /> | **[[1xdd]], [[1xdg]], [[1xuo]], [[7kc5]] - hIG I domain + inhibitor + Mg<br /> | ||
**[[7kc6]] - hIG I domain + drug + Mg<br /> | |||
**[[3f78]] - hIG I domain + anesthetic + Mg<br /> | **[[3f78]] - hIG I domain + anesthetic + Mg<br /> | ||
**[[3eoa]], [[3eob]] - hIG I domain + antibody<br /> | **[[3eoa]], [[3eob]] - hIG I domain + antibody<br /> | ||
**[[3hi6]] - hIG I domain (mutant) + antibody + Mn<br /> | **[[3hi6]] - hIG I domain (mutant) + antibody + Mn<br /> | ||
*IG α-L + IG β-2 | |||
**[[5e6u]] – hIG headpiece (mutant) + Ni<br /> | |||
*IG α-M | *IG α-M | ||
Line 126: | Line 132: | ||
**[[3q3g]], [[3qa3]] – hIG + antibody<br /> | **[[3q3g]], [[3qa3]] – hIG + antibody<br /> | ||
**[[4m76]] – hIG + complement C3<br /> | **[[4m76]] – hIG + complement C3<br /> | ||
**[[2lke]], [[2lkj – hIG cytoplasmic domain – NMR<br /> | **[[2lke]], [[2lkj]] – hIG cytoplasmic domain – NMR<br /> | ||
**[[4xw2]] – hIG + simvastatin<br /> | **[[4xw2]] – hIG + simvastatin<br /> | ||
**[[6rhv]], [[6rhw]] – hIG + cytolysin<br /> | **[[6rhv]], [[6rhw]] – hIG + cytolysin<br /> | ||
*IG α-M + IG β-2 | |||
**[[7usm]] – hIG ectodomain – Cryo EM<br /> | |||
**[[7usl]] – hIG ectodomain + adenylate cyclase toxin + antibody – Cryo EM<br /> | |||
**[[ | **[[7p2d]] – hIG ectodomain + nanobody <br /> | ||
**[[ | |||
**[[ | |||
*IG α-V + IG β-3 | *IG α-V + IG β-3 | ||
Line 154: | Line 155: | ||
**[[6om2]] – hIG (mutant) + Protgf-b1 RGD peptide<br /> | **[[6om2]] – hIG (mutant) + Protgf-b1 RGD peptide<br /> | ||
**[[6uja]] – hIG + Protgf-b1 RGD – Cryo EM<br /> | **[[6uja]] – hIG + Protgf-b1 RGD – Cryo EM<br /> | ||
**[[7y1t]] – hIG + TGF-b1 – Cryo EM<br /> | |||
*IG α-X | *IG α-X |
Latest revision as of 11:32, 31 May 2023
3D structures of integrin3D structures of integrin
Updated on 31-May-2023
- 4irz - hIG + antibody
- 4irz - hIG + antibody
- IG α-4 (CD49d) + IG β-7
- IG α-5 (CD49e) + IG β-1 (CD29)
- IG α-5 (CD49e) + IG β-3 (CD61) ectodomain
- IG α-5 + IG β-6
- IG α-6 + IG β-1
- IG α-L
- 1lfa - hIG I domain + Mn
- 1zon, 4ixd, 7kc3 - hIG I domain 153-334
- 1mqa - hIG I domain (mutant)
- 1zoo, 1zop, 3f74 - hIG I domain + Mg
- 1mq9 - hIG I domain (mutant) + Mn
- 1mjn - hIG I domain (mutant) + Mg
- 2k8o – hIG cytoplasmic domain (mutant) – NMR
- 5e6s, 5e6r – hIG AI, headpiece,pocket domains + Mg
- 2m3e – hIG transmembrane domain - NMR
- 1lfa - hIG I domain + Mn
- IG α-L complexes
- 1cqp - hIG I domain + lovastatin + Mg
- 1mq8, 3bn3, 3tcx - hIG I domain (mutant) + intracellular adhesion molecule + Mg
- 1t0p - hIG I domain + intracellular adhesion molecule-3 + Mg
- 1rd4, 2ica, 3bqm, 3bqn, 3e2m - hIG I domain + inhibitor
- 2o7n, 3m6f - hIG I domain + antagonist
- 1xdd, 1xdg, 1xuo, 7kc5 - hIG I domain + inhibitor + Mg
- 7kc6 - hIG I domain + drug + Mg
- 3f78 - hIG I domain + anesthetic + Mg
- 3eoa, 3eob - hIG I domain + antibody
- 3hi6 - hIG I domain (mutant) + antibody + Mn
- 1cqp - hIG I domain + lovastatin + Mg
- IG α-L + IG β-2
- 5e6u – hIG headpiece (mutant) + Ni
- 5e6u – hIG headpiece (mutant) + Ni
- IG α-M
- IG α-M + IG β-2
- IG α-V + IG β-3
- IG α-V + IG β-8
- IG α-X
- IG α-X + IG β-2 (CD18)
- IG β-1D
- 3g9w – hIG cytoplasmic tail + talin 2 F2-F3 domain
- 3g9w – hIG cytoplasmic tail + talin 2 F2-F3 domain
- IG β-2 (CD18)
- IG β-3 (CD61)
- IG β-4 (CD104; Gp150)
- 2f7q, 3f7r, 1qg3, 3f7q, 4wtw, 4wtx - hIG fibronectin type III domain
- 2yrz – hIG fibronectin type III domain – NMR
- 3f7p, 4q58 - hIG fibronectin type III domain + plectin-1
- 6gvl - hIG fibronectin type III domain + dystonin
- 6gvk - hIG fibronectin type III domain (mutant) + dystonin
- 3fq4, 3fso, 3h6a – hIG Calx-β domain
- 6hyf - rIG fibronectin type III domain
- 2f7q, 3f7r, 1qg3, 3f7q, 4wtw, 4wtx - hIG fibronectin type III domain
- IG β-7